Singapore-based healthcare company Zuellig Pharma has announced the establishment of a commercialization partnership with France-based Substipharm Biologics. The partnership centers around Substipharm’s Japanese encephalitis (JE) vaccine, Imojev. Zuellig Pharma will offer marketing and distribution support, aiming to make the vaccine accessible to patients across nine Asian markets, including Brunei, Cambodia, Hong Kong, Malaysia, Myanmar, Philippines, Singapore, Taiwan, and Vietnam.
The agreement also encompasses the expansion of Zuellig’s warehousing and distribution (W&D) services to Substipharm in Taiwan, supplementing existing services in Brunei and Thailand. Financial details of the deal were not disclosed. Substipharm had acquired the global development rights for the Imojev vaccine from Sanofi in a 2022 transaction.- Flcube.com
